Abstracts tagged "Psoriatic arthritis"

Abstract Number: 437 • 2019 ACR/ARP Annual Meeting
Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?
Rubén Queiro¹, Estefania Pardo ¹, Lilyan Charca ¹, Sara Alonso ¹, L. Arboleya ² and Mercedes Alperi-López ¹, ¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²Hospital Central Asturias, OViedo
Background/Purpose: Psoriatic arthritis (PsA) is accompanied by a high prevalence cardiovascular (CV) comorbidity. This comorbidity has been associated with worse therapeutic results as well as…
Abstract Number: 1086 • 2019 ACR/ARP Annual Meeting
Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
Jürgen Rech¹, Michael Sticherling ², Mona Biermann ³, Benjamin Häberle ³ and Maximilian Reinhardt ⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Bayern, Germany, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Bayern, Germany, ⁴Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany
Background/Purpose: Psoriasis (PsO) is a systemic inflammatory disease accompanied by comorbidities such as depression, cardiovascular diseases or metabolic syndrome. Approximately 10 - 27% of PsO…
Abstract Number: 1483 • 2019 ACR/ARP Annual Meeting
Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study
Lyn Ferguson¹, Paul Welsh ¹, Rosemary Brown ¹, Alistair Tindell ², Sean Kerrigan ³, Naveed Sattar ¹, Iain McInnes ⁴ and Stefan Siebert ⁴, ¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, Glasgow, ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is associated with obesity and increased cardiometabolic risk. Weight loss has been noted in association with the phosphodiesterase 4 (PDE4) inhibitor…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Xintong Li ¹, Kathleen M Andersen², Hsien-Yen Chang ³, G. Caleb Alexander ⁴ and Jeffrey Curtis ⁵, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, ⁴Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
Abstract Number: 2454 • 2019 ACR/ARP Annual Meeting
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Ana-Maria Orbai¹, Rebecca Manno ², Jamie Perin ³, Noori Kim ⁴, Katherine C. Smith ⁵, Albert W Wu ⁶, Clifton Bingham ⁷ and Uzma Haque ², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ⁴Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, MD, ⁵Johns Hopkins University Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, ⁶Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using…
Abstract Number: 2475 • 2019 ACR/ARP Annual Meeting
Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Peter Hur ², Mei Liu ³, Sabrina Rebello ³, Robert McLean ³, Blessing Dube ³, Meghan Glynn ⁴ and Philip Mease ⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease of the skin and musculoskeletal system. Six key domains of PsA have been identified to…
Abstract Number: 2498 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study
Sahil Koppikar¹, Keith Colaco ², Paula Harvey ³, Vinod Chandran ⁴, Dafna Gladman ⁵, Richard Cook ⁶ and Lihi Eder ⁷, ¹University of Toronto, Markham, ON, Canada, ²University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada, ⁷Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: Data about heart failure (HF) in patients with psoriatic disease (PsD) are sparse. The aims of the study were to: 1) determine the incidence…
Abstract Number: 2852 • 2019 ACR/ARP Annual Meeting
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie¹, Xingmei Wang ¹, Thorvardur J Love ², Telma Thrastardottir ³, Maureen Dubreuil ⁴ and Joel Gelfand ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³University of Iceland, Reykjavik, Iceland, ⁴Boston University School of Medicine, Boston, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors…
Abstract Number: 582 • 2019 ACR/ARP Annual Meeting
Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Einer Sanchez Prado¹, Alvaro Ruta ², Jessica Torres Chichande ², Santiago Ruta ³, Sebastian Magri ², Facundo Salvatori ² and Rodrigo Garcia Salinas ², ¹Hospital Italiano de La Plata, La Plata, ²Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ³Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina
Background/Purpose: In our region, the lack of knowledge, timely referral and access to laboratory tests and images are the main causes in the diagnostic delay…
Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Klaus Krüger¹, Sven Remstedt ², Astrid Thiele ³ and Ines Klaudius ⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…
Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Peter Nash¹, Maria Greenwald ², Liang-Hung Lin ³, Wei Yu ⁴, Paul Santos Estrella ⁵, Rajiv Mundayat ⁶, Daniela Graham ⁷ and Douglas Veale ⁸, ¹University of Queensland, Brisbane, Queensland, Australia, ²Desert Medical Advances, Palm Desert, CA, ³AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), ⁴Pfizer Inc, Beijing, China (People's Republic), ⁵Pfizer Inc, Makati, Philippines, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
Abstract Number: 1534 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Laura Coates¹, Philip Mease ², Dafna Gladman ³, Filip Van den Bosch ⁴, Anna Rychlewska-Hanczewska ⁵, Chantal Tasset ⁶, Luc Meuleners ⁶, Mona Trivedi ⁷, Jingjing Gao ⁷, Robin Besuyen ⁶ and Philip Helliwell ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵5ai centrum medyczne sp. z o.o. sp.k., Poznan, Poland, Poznan, Poland, ⁶Galapagos NV, Mechelen, Belgium, ⁷Gilead Sciences Inc, Foster City, United States of America, Foster City, CA, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Filgotinib (FIL) is an orally administered, selective Janus Kinase 1 (JAK1) inhibitor in development for psoriatic arthritis (PsA). Efficacy and safety of FIL in…
Abstract Number: 2246 • 2019 ACR/ARP Annual Meeting
Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Kaleb Michaud ¹, Evo Alemao ², Miroslawa Nowak ³, Rachel Bruce ⁴, Sarah Cantor ⁴, Carlijn Hintzen ⁵, Philip Mease ⁶, Kendra DeBusk² and Alexis Ogdie ⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴IQVIA, New York, ⁵IQVIA, Amsterdam, Netherlands, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁷University of Pennsylvania, Philadelphia
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease resulting in significant symptom burden.1 Over time and without adequate treatment, PsA can lead to disability…
Abstract Number: 2455 • 2019 ACR/ARP Annual Meeting
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Ana-Maria Orbai¹, Birt Julie ², Elizabeth Holdsworth ³, Nicola Booth ⁴, Matthew M. Hufford ², Malatestinic William ², Aubrey Trevelin Sprabery ² and Anthony Reginato ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Division of Rheumatology, Providence VAMC, Associate Professor in Medicine, The Warren Alpert School of Medicine, Providence
Background/Purpose: Enthesitis, a characteristic clinical feature of psoriatic arthritis (PsA) [1], is a core outcome for PsA clinical trials. While enthesitis is considered important when…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].